Tango Therapeutics (TNGX) EBITDA Margin (2020 - 2025)
Historic EBITDA Margin for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to 26.15%.
- Tango Therapeutics' EBITDA Margin rose 3094100.0% to 26.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 165.91%, marking a year-over-year increase of 1353100.0%. This contributed to the annual value of 309.38% for FY2024, which is 414900.0% down from last year.
- According to the latest figures from Q3 2025, Tango Therapeutics' EBITDA Margin is 26.15%, which was up 3094100.0% from 1287.87% recorded in Q2 2025.
- In the past 5 years, Tango Therapeutics' EBITDA Margin ranged from a high of 26.15% in Q3 2025 and a low of 1287.87% during Q2 2025
- Its 5-year average for EBITDA Margin is 426.89%, with a median of 427.15% in 2022.
- In the last 5 years, Tango Therapeutics' EBITDA Margin soared by 3097900bps in 2023 and then plummeted by -11391800bps in 2025.
- Over the past 5 years, Tango Therapeutics' EBITDA Margin (Quarter) stood at 398.9% in 2021, then decreased by -9bps to 435.33% in 2022, then fell by -26bps to 550.47% in 2023, then crashed by -81bps to 993.68% in 2024, then soared by 103bps to 26.15% in 2025.
- Its last three reported values are 26.15% in Q3 2025, 1287.87% for Q2 2025, and 788.76% during Q1 2025.